SEC Company Response from Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830) (TVRD) — Feb 14, 2025
Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830)
Date: Feb. 14, 2025 · CIK: 0001346830 · Accession: 0001104659-25-013753
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283900
Letter
Cara Therapeutics, Inc.
400 Atlantic Street
Suite 500
Stamford, CT 06901
February 14, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE: Cara Therapeutics, Inc.
Registration Statement on Form S-4 File No. 333-283900
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Cara Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the Registration Statement on Form S-4 (File No. 333-283900), as amended (the “Registration Statement”), so that it may become effective at 5:00 p.m., Washington, D.C. time, on February 14, 2025, or as soon as possible thereafter.
The Company hereby authorizes Daniel A. Bagliebter, Esq. and Jeffrey P. Schultz, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to orally modify or withdraw this request for acceleration.
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Mr. Bagliebter at (212) 692-6856 and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Mr. Bagliebter.
Very truly yours,
CARA THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Cara Therapeutics, Inc.
400 Atlantic Street
Suite 500
Stamford, CT 06901
February 14, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE:
Cara Therapeutics, Inc.
Registration Statement on Form S-4 File
No. 333-283900
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under
the Securities Act of 1933, as amended, Cara Therapeutics, Inc. (the “Company”) hereby requests acceleration
of the effective date of the Registration Statement on Form S-4 (File No. 333-283900), as amended (the “Registration
Statement”), so that it may become effective at 5:00 p.m., Washington, D.C. time, on February 14, 2025, or as soon as possible
thereafter.
The Company hereby authorizes Daniel A. Bagliebter, Esq.
and Jeffrey P. Schultz, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to orally modify or withdraw this request for acceleration.
The Company respectfully requests that it be notified
of such effectiveness by a telephone call to Mr. Bagliebter at (212) 692-6856 and that such effectiveness also be confirmed in writing.
Any questions regarding this request may be addressed to Mr. Bagliebter.
Very truly yours,
CARA THERAPEUTICS, INC.
/s/ Christopher Posner
Christopher Posner
President and Chief Executive Officer
cc:
Cara Therapeutics, Inc.
Scott Terrillion, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.
Daniel A. Bagliebter, Esq.
Jeffrey P. Schultz, Esq
Tvardi Therapeutics, Inc.
Imran Alibhai
Cooley
LLP
Rama Padmanabhan, Esq.
Carlos Ramirez, Esq.